183 related articles for article (PubMed ID: 21498309)
21. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
22. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
23. (18)F-Choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer.
Kwee SA; Coel MN; Ly BH; Lim J
Ann Nucl Med; 2009 Aug; 23(6):541-8. PubMed ID: 19529978
[TBL] [Abstract][Full Text] [Related]
24. Prospective comparative study of
Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases.
Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA
Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313
[TBL] [Abstract][Full Text] [Related]
26. The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy.
Begic A; Kucukalic-Selimovic E; Obralic N; Duric O; Lacevic N; Begovic-Hadzimuratovic S; Skopljak A; Dzubur-Aganovic M
Med Arh; 2006; 60(1):54-5. PubMed ID: 16425536
[TBL] [Abstract][Full Text] [Related]
27. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2009; 11(6):446-54. PubMed ID: 19326171
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer.
Acar E; Bekiş R; Polack B
Curr Med Imaging Rev; 2019; 15(6):589-594. PubMed ID: 32008568
[TBL] [Abstract][Full Text] [Related]
29.
Langsteger W; Rezaee A; Pirich C; Beheshti M
Semin Nucl Med; 2016 Nov; 46(6):491-501. PubMed ID: 27825429
[No Abstract] [Full Text] [Related]
30. Spectral parametric segmentation of contrast-enhanced dual-energy CT to detect bone metastasis: feasibility sensitivity study using whole-body bone scintigraphy.
Lee YH; Kim S; Lim D; Suh JS; Song HT
Acta Radiol; 2015 Apr; 56(4):458-64. PubMed ID: 24714734
[TBL] [Abstract][Full Text] [Related]
31. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
32. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment.
Yahara J; Noguchi M; Noda S
BJU Int; 2003 Sep; 92(4):379-83; discussion 383-4. PubMed ID: 12930424
[TBL] [Abstract][Full Text] [Related]
33. [Flare response on bone scintigraphy in metastatic prostate cancer].
Aizawa T; Tochimoto M; Ito T; Tsujino S; Akiyama A; Namiki K; Miki M; Ueda M
Nihon Hinyokika Gakkai Zasshi; 1994 May; 85(5):815-8. PubMed ID: 8022146
[TBL] [Abstract][Full Text] [Related]
34. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
Iagaru A; Mittra E; Dick DW; Gambhir SS
Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Ga-68 PSMA positron emission tomography/computerized tomography with Tc-99m MDP bone scan in prostate cancer patients.
Uslu-Beşli L; Sağer S; Akgün E; Asa S; Şahin OE; Demirdağ Ç; Güner E; Khosroshahi BR; Karayel E; Pehlivanoğlu H; Aygün A; Uslu İ; Talat Z; Sönmezoğlu K
Turk J Med Sci; 2019 Feb; 49(1):301-310. PubMed ID: 30761859
[TBL] [Abstract][Full Text] [Related]
38. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer.
Schneider JA; Divgi CR; Scott AM; Macapinlac HA; Seidman AD; Goldsmith SJ; Larson SM
J Nucl Med; 1994 Nov; 35(11):1748-52. PubMed ID: 7525900
[TBL] [Abstract][Full Text] [Related]
39. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer].
Garcia JR; Moreno C; Valls E; Cozar P; Bassa P; Soler M; Alvarez-Moro FJ; Moragas M; Riera E
Rev Esp Med Nucl Imagen Mol; 2015; 34(3):155-61. PubMed ID: 25443648
[TBL] [Abstract][Full Text] [Related]
40. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
